Do analysts prefer SLDB or GMTX?

Solid Biosciences currently has a consensus target price of $17.11, indicating a potential upside of 85.99%. Given Solid Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Solid Biosciences is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solid Biosciences 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.91 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, SLDB or GMTX?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solid Biosciences N/A N/A -$174.32M -$1.91 N/A Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A

Is SLDB or GMTX more profitable?

Gemini Therapeutics' return on equity of -38.78% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -71.35% -60.58% Gemini Therapeutics N/A -38.78% -35.88%

Is SLDB or CLDX more profitable?

Celldex Therapeutics' return on equity of -52.35% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -71.35% -60.58% Celldex Therapeutics N/A -52.35% -47.61%

Does the media refer more to SLDB or CLDX?

In the previous week, Celldex Therapeutics had 1 more articles in the media than Solid Biosciences. MarketBeat recorded 17 mentions for Celldex Therapeutics and 16 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.98 beat Celldex Therapeutics' score of 0.79 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, SLDB or MBX?

MBX Biosciences is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solid Biosciences N/A N/A -$174.32M -$1.91 N/A MBX Biosciences N/A N/A -$86.97M -$2.41 N/A

Is SLDB or MBX more profitable?

MBX Biosciences' return on equity of -26.02% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -71.35% -60.58% MBX Biosciences N/A -26.02% -24.94%

Does the media favor SLDB or MBX?

In the previous week, Solid Biosciences had 11 more articles in the media than MBX Biosciences. MarketBeat recorded 16 mentions for Solid Biosciences and 5 mentions for MBX Biosciences. Solid Biosciences' average media sentiment score of 0.98 beat MBX Biosciences' score of 0.82 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MBX Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SLDB or NAMS?

In the previous week, Solid Biosciences had 9 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 16 mentions for Solid Biosciences and 7 mentions for NewAmsterdam Pharma. Solid Biosciences' average media sentiment score of 0.98 beat NewAmsterdam Pharma's score of -0.11 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SLDB or GRAL more profitable?

Solid Biosciences has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -71.35% -60.58% GRAIL -236.95% -15.88% -14.02%

Does the media favor SLDB or GRAL?

In the previous week, Solid Biosciences had 6 more articles in the media than GRAIL. MarketBeat recorded 16 mentions for Solid Biosciences and 10 mentions for GRAIL. GRAIL's average media sentiment score of 1.00 beat Solid Biosciences' score of 0.98 indicating that GRAIL is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GRAIL 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Solid Biosciences (SLDB) Competitors

$9.20 +0.12 (+1.32%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$9.26 +0.07 (+0.71%)

As of 08/14/2026 07:38 PM Eastern

Compare

SLDB vs. GMTX, CLDX, MBX, NAMS, and GRAL

Should you buy Solid Biosciences stock or one of its competitors? Solid Biosciences's main competitors and comparable companies include Gemini Therapeutics (GMTX), Celldex Therapeutics (CLDX), MBX Biosciences (MBX), NewAmsterdam Pharma (NAMS), and GRAIL (GRAL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Solid Biosciences compare to Gemini Therapeutics?

Solid Biosciences (NASDAQ:SLDB) and Gemini Therapeutics (NASDAQ:GMTX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Gemini Therapeutics' return on equity of -38.78% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
Gemini Therapeutics	N/A	-38.78%	-35.88%

In the previous week, Solid Biosciences had 16 more articles in the media than Gemini Therapeutics. MarketBeat recorded 16 mentions for Solid Biosciences and 0 mentions for Gemini Therapeutics. Solid Biosciences' average media sentiment score of 0.98 beat Gemini Therapeutics' score of 0.00 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Solid Biosciences	Positive
Gemini Therapeutics	Neutral

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Solid Biosciences currently has a consensus target price of $17.11, indicating a potential upside of 85.99%. Given Solid Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Solid Biosciences is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Solid Biosciences has a beta of 2.41, indicating that its share price is 141% more volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market.

Summary

Solid Biosciences beats Gemini Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Solid Biosciences compare to Celldex Therapeutics?

Solid Biosciences (NASDAQ:SLDB) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Solid Biosciences presently has a consensus price target of $17.11, indicating a potential upside of 85.99%. Celldex Therapeutics has a consensus price target of $55.46, indicating a potential upside of 32.21%. Given Solid Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Solid Biosciences is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Solid Biosciences has higher earnings, but lower revenue than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
Celldex Therapeutics	$158K	20,850.21	-$258.76M	-$4.35	N/A

In the previous week, Celldex Therapeutics had 1 more articles in the media than Solid Biosciences. MarketBeat recorded 17 mentions for Celldex Therapeutics and 16 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.98 beat Celldex Therapeutics' score of 0.79 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Celldex Therapeutics' return on equity of -52.35% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
Celldex Therapeutics	N/A	-52.35%	-47.61%

Solid Biosciences has a beta of 2.41, suggesting that its share price is 141% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

81.5% of Solid Biosciences shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Solid Biosciences beats Celldex Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Solid Biosciences compare to MBX Biosciences?

Solid Biosciences (NASDAQ:SLDB) and MBX Biosciences (NASDAQ:MBX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Solid Biosciences has a beta of 2.41, meaning that its share price is 141% more volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market.

Solid Biosciences presently has a consensus target price of $17.11, indicating a potential upside of 85.99%. MBX Biosciences has a consensus target price of $75.63, indicating a potential upside of 10.29%. Given Solid Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Solid Biosciences is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

81.5% of Solid Biosciences shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by insiders. Comparatively, 31.1% of MBX Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

MBX Biosciences is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

In the previous week, Solid Biosciences had 11 more articles in the media than MBX Biosciences. MarketBeat recorded 16 mentions for Solid Biosciences and 5 mentions for MBX Biosciences. Solid Biosciences' average media sentiment score of 0.98 beat MBX Biosciences' score of 0.82 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MBX Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MBX Biosciences' return on equity of -26.02% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
MBX Biosciences	N/A	-26.02%	-24.94%

Summary

Solid Biosciences beats MBX Biosciences on 8 of the 12 factors compared between the two stocks.

How does Solid Biosciences compare to NewAmsterdam Pharma?

Solid Biosciences (NASDAQ:SLDB) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

In the previous week, Solid Biosciences had 9 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 16 mentions for Solid Biosciences and 7 mentions for NewAmsterdam Pharma. Solid Biosciences' average media sentiment score of 0.98 beat NewAmsterdam Pharma's score of -0.11 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Solid Biosciences has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

Solid Biosciences has higher earnings, but lower revenue than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
NewAmsterdam Pharma	$22.50M	143.34	-$203.82M	-$2.16	N/A

Solid Biosciences currently has a consensus target price of $17.11, suggesting a potential upside of 85.99%. NewAmsterdam Pharma has a consensus target price of $49.33, suggesting a potential upside of 82.85%. Given Solid Biosciences' higher possible upside, research analysts plainly believe Solid Biosciences is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Solid Biosciences has a beta of 2.41, meaning that its share price is 141% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market.

Summary

Solid Biosciences and NewAmsterdam Pharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Solid Biosciences compare to GRAIL?

Solid Biosciences (NASDAQ:SLDB) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

In the previous week, Solid Biosciences had 6 more articles in the media than GRAIL. MarketBeat recorded 16 mentions for Solid Biosciences and 10 mentions for GRAIL. GRAIL's average media sentiment score of 1.00 beat Solid Biosciences' score of 0.98 indicating that GRAIL is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GRAIL	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solid Biosciences currently has a consensus price target of $17.11, indicating a potential upside of 85.99%. GRAIL has a consensus price target of $67.78, indicating a potential downside of 0.14%. Given Solid Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Solid Biosciences is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

Solid Biosciences has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
GRAIL	-236.95%	-15.88%	-14.02%

81.5% of Solid Biosciences shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by company insiders. Comparatively, 1.8% of GRAIL shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Solid Biosciences has a beta of 2.41, suggesting that its share price is 141% more volatile than the broader market. Comparatively, GRAIL has a beta of 3.24, suggesting that its share price is 224% more volatile than the broader market.

Solid Biosciences has higher earnings, but lower revenue than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
GRAIL	$165.26M	18.34	-$408.35M	-$9.75	N/A

Summary

Solid Biosciences beats GRAIL on 11 of the 16 factors compared between the two stocks.

Get Solid Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLDB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLDB vs. The Competition

Export

Metric	Solid Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$973.60M	$3.71B	$7.02B	$13.06B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-4.82	10.78	271.27	25.33
Price / Sales	N/A	1,268.77	588.55	78.45
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	2.64	16.78	12.92	6.25
Net Income	-$174.32M	-$13.32M	$3.45B	$347.82M
7 Day Performance	9.65%	1.76%	1.16%	1.08%
1 Month Performance	-4.37%	1.14%	1.37%	0.82%
1 Year Performance	50.57%	54.35%	62.53%	20.99%

Solid Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLDB Solid Biosciences	2.2829 of 5 stars	$9.20 +1.3%	$17.11 +86.0%	+49.1%	$973.60M	N/A	N/A	100	Analyst Revision
GMTX Gemini Therapeutics	N/A	$78.91 +1.4%	N/A	+30.9%	$3.42B	N/A	N/A	30
CLDX Celldex Therapeutics	2.9125 of 5 stars	$41.56 +1.2%	$54.62 +31.4%	+68.2%	$3.22B	$1.54M	N/A	150	Analyst Revision
MBX MBX Biosciences	2.4334 of 5 stars	$67.11 -0.5%	$71.13 +6.0%	N/A	$3.21B	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	2.5657 of 5 stars	$27.67 +0.9%	$49.33 +78.3%	+7.2%	$3.21B	$22.57M	N/A	4

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLDB) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Solid Biosciences (SLDB) Competitors

SLDB vs. GMTX, CLDX, MBX, NAMS, and GRAL

How does Solid Biosciences compare to Gemini Therapeutics?

Summary

How does Solid Biosciences compare to Celldex Therapeutics?

Summary

How does Solid Biosciences compare to MBX Biosciences?

Summary

How does Solid Biosciences compare to NewAmsterdam Pharma?

Summary

How does Solid Biosciences compare to GRAIL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB vs. The Competition

Solid Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Solid Biosciences (SLDB) Competitors

SLDB vs. GMTX, CLDX, MBX, NAMS, and GRAL

How does Solid Biosciences compare to Gemini Therapeutics?

Do institutionals and insiders believe in SLDB or GMTX?

Is SLDB or GMTX more profitable?

Does the media favor SLDB or GMTX?

Which has higher valuation and earnings, SLDB or GMTX?

Do analysts prefer SLDB or GMTX?

Which has more risk & volatility, SLDB or GMTX?

Summary

How does Solid Biosciences compare to Celldex Therapeutics?

Do analysts prefer SLDB or CLDX?

Which has preferable earnings & valuation, SLDB or CLDX?

Does the media refer more to SLDB or CLDX?

Is SLDB or CLDX more profitable?

Which has more volatility and risk, SLDB or CLDX?

Do institutionals and insiders believe in SLDB or CLDX?

Summary

How does Solid Biosciences compare to MBX Biosciences?

Which has more volatility & risk, SLDB or MBX?

Do analysts rate SLDB or MBX?

Do institutionals & insiders hold more shares of SLDB or MBX?

Which has preferable valuation & earnings, SLDB or MBX?

Does the media favor SLDB or MBX?

Is SLDB or MBX more profitable?

Summary

How does Solid Biosciences compare to NewAmsterdam Pharma?

Does the media refer more to SLDB or NAMS?

Is SLDB or NAMS more profitable?

Which has better valuation and earnings, SLDB or NAMS?

Do analysts recommend SLDB or NAMS?

Do institutionals and insiders have more ownership in SLDB or NAMS?

Which has more volatility & risk, SLDB or NAMS?

Summary

How does Solid Biosciences compare to GRAIL?

Does the media favor SLDB or GRAL?

Do analysts prefer SLDB or GRAL?

Is SLDB or GRAL more profitable?

Do institutionals & insiders have more ownership in SLDB or GRAL?

Which has more risk and volatility, SLDB or GRAL?

Which has better valuation and earnings, SLDB or GRAL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB vs. The Competition

Solid Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools